---
title: "Dexcom Inc 2026: Revenue $1.31B, EPS $0.64— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294419965.md"
description: "Dexcom Inc reported Q2 2026 results with revenue of $1.31B, up 13.1% YoY, and diluted EPS of $0.64, up 42.2%. Net income reached $249.1M. Growth was driven by higher disposable sensor volume and favorable revenue per customer. Gross margin improved to 63%, supported by manufacturing efficiencies and product momentum from G7 15 Day and Stelo OTC biosensors."
datetime: "2026-07-30T21:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294419965.md)
  - [en](https://longbridge.com/en/news/294419965.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294419965.md)
generator: "portal-rs"
---

# Dexcom Inc 2026: Revenue $1.31B, EPS $0.64— 10-Q Summary

Dexcom Inc reported second-quarter 2026 results with revenue of $1.31B, net income of $249.1M and diluted EPS of $0.64, all ahead of the prior-year quarter as the company continued to expand its customer base and improve margins.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$1.31B

$1.16B

13.1%

Net income²

$249.1M

$179.8M

38.5%

Diluted EPS³

$0.64

$0.45

42.2%

*¹ Reported as “Revenue”. ² Reported as “Net income”. ³ Reported as “Diluted net income per share”.*

**Business Highlights**

-   Revenue grew 13% year over year to $1.31B, driven by higher disposable sensor volume and favorable revenue per customer.
-   The distributor channel remained the primary sales route, accounting for roughly 84% of Q2 revenue, while direct international sales expanded.
-   Product momentum continued with the G7 15 Day (launched 2025) and the Stelo OTC biosensor (Aug 2024), broadening consumer and prediabetes reach.
-   Gross margin improved to 63%, aided by higher volumes, benefits from G7 15 Day and manufacturing efficiencies despite costs related to phasing out G6.
-   Worldwide customer growth remained strong, with substantial net additions in the prior year period that increased utilization and improved payor mix.

Original SEC Filing: DEXCOM INC \[ DXCM \] - 10-Q - Jul. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [DXCM.US](https://longbridge.com/en/quote/DXCM.US.md)

## Related News & Research

- [G7 Momentum and Global Reach Might Change The Case For Investing In DexCom (DXCM)](https://longbridge.com/en/news/297620389.md)
- [DexCom to present at Wells Fargo annual healthcare conference](https://longbridge.com/en/news/297653036.md)
- [Broadridge expands distributed-ledger repo network to include G7 securities](https://longbridge.com/en/news/297738472.md)
- [13:01 ETTopDoctor Magazine Invites Physicians and Longevity Leaders to Biohackers World Chicago This Weekend](https://longbridge.com/en/news/297942843.md)
- [Broadridge Brings G7 Securities to Institutional Tokenized Repo | BR Stock News](https://longbridge.com/en/news/297739127.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**